Zum Hauptinhalt springen

Alopecia Severity Endpoints for Clinical Trials

The AI scoring provided by Legit.Health delivers automated, standardised alopecia severity scoring for clinical trials, measuring scalp hair loss in each of the four SALT quadrants from standardised photographs to compute the Severity of Alopecia Tool (SALT) score, the standard measure of the extent of scalp hair loss in alopecia areata trials.

The device supports interventional and observational studies across all clinical trial phases, from Phase I to Phase IV, as well as real-world evidence (RWE) and post-marketing studies.

Severity of Alopecia Tool

SALT66Severe

0 to 100 scale, four weighted scalp quadrants

Images analysed

4 (top, back, left and right)

Analysis performed in

1.2 seconds

AI segmentation: Top

Body site

Top

Image quality

63%

Hair loss

62%

Severe

SALT points

25

40% of the scalp

AI segmentation: Back

Body site

Back

Image quality

55%

Hair loss

70%

Severe

SALT points

17

24% of the scalp

AI segmentation: Left side

Body site

Left side

Image quality

68%

Hair loss

66%

Severe

SALT points

12

18% of the scalp

AI segmentation: Right side

Body site

Right side

Image quality

66%

Hair loss

68%

Severe

SALT points

12

18% of the scalp

SALT = 25 + 17 + 12 + 12 = 66

The validation of the model behind these scores is on Clinical evidence.

The example images on this page are synthetic dermatology imagery used for illustration; they are not patient records.

Why automated SALT scoring for clinical trials?​

Manual SALT asks a rater to estimate by eye the percentage of hair loss in each of four scalp quadrants, four separate judgements per patient per visit, usually made in coarse steps. Estimating that percentage is the most operator-dependent step of the score, and two raters looking at the same scalp often land on different values.

The AI automates every component of the score:

  • Hair loss measurement: pixel-level segmentation of hair, hair loss and non-scalp in each of the four quadrant photographs, replacing visual estimation
  • SALT calculation: the four quadrant percentages combined with the standard SALT weights into the total score, from 0 to 100
  • DIQA (Dermatology Image Quality Assessment): image quality assessed before scoring, so substandard images are flagged for recapture at the visit rather than surfacing as missing data at database lock

The four photographs follow a standardised capture protocol, so every visit is photographed the same way; see Imaging protocol.

Why this matters for your trial

Automated SALT returns a continuous measurement from standardised photographs, with three properties manual scoring cannot offer:

  • Perfect reproducibility: the same image always produces the same score, with zero intra-rater variability, at every site and every visit.
  • No investigator training drift: performance does not depend on how recently a site was trained or on which rater is on shift that day.
  • Less noise in SALT change from baseline, which can support smaller sample sizes or greater statistical power to detect treatment response, once agreement with investigator scoring is confirmed.

Endpoint capabilities​

The AI reports the SALT score and its four regional components from a single capture set, configurable per study protocol:

SALTSeverity of Alopecia Tool
Total score
0 to 100
The percentage of the whole scalp without hair
Structure
4 weighted quadrants
Top 40%, back 24%, left side 18% and right side 18% of the scalp
Regional extent
0 to 100% per quadrant
Hair loss in each quadrant, measured at pixel level, not estimated
Granularity
Per quadrant
Quadrant percentages feed the SALT and show where hair is lost or regrown
SALT and responder definitions

SALT is the efficacy measure of alopecia areata programmes, and every responder definition is read from the same score; see SALT response thresholds. The regional percentages are reported alongside, because they show which part of the scalp drives the change.

How the AI works​

For each of the four photographs, a deep learning model detects the scalp and classifies every pixel of it as hair or no hair, leaving the background, the face and the ears out. It then measures the percentage of the scalp affected by hair loss in that view, and the four percentages are combined into the SALT score.

Left side of the scalp: hair-bearing scalp with patches of hair loss
Left side
Right side of the scalp: hair-bearing scalp with patches of hair loss
Right side
Back of the scalp: hair-bearing scalp with patches of hair loss
Back
Top of the scalp: hair-bearing scalp with patches of hair loss
Top

The segmentation mask appears over the original photograph, so the investigator sees exactly which areas were counted as hair loss:

Top of the scalp
‹›
SegmentationPhotograph
SALT calculation

Top of the scalp

The quadrant shown in the slider

Partial SALTHair loss in the quadrantShare of the scalp
25 points62%40%
62% × 0.40 = 24.8 of the 66 points of the total SALT

Automated analysis of a scalp: pixel-level segmentation and the SALT calculation, with illustrative values

Longitudinal severity tracking​

From the follow-up visits onward, the same report shows how severity evolves across the study:

  • SALT trajectory: absolute and percentage change from baseline at each visit, from screening to end of study
  • Responder definitions: whether the patient has reached SALT 20 or less, SALT 50, SALT 75 or SALT 90, derived from the per-visit scores
  • Per-quadrant trends: which part of the scalp is driving regrowth or further loss
  • Alerts against baseline: a notification to the site when hair loss increases by the configured threshold, which also supports adverse event monitoring in trials outside dermatology
  • Protocol adherence: whether assessments are captured at the correct intervals

For follow-up visits, the platform charts this severity evolution across all assessments for the patient:

Severity chart
Intended use

The platform provides automated severity scoring as decision support. Scores are interpreted by qualified healthcare professionals within the patient's overall clinical context; the platform does not replace clinical judgement or make autonomous diagnostic decisions.